Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 23 | 2025 | 426 | 5.160 |
Why?
|
| Cocaine-Related Disorders | 21 | 2025 | 206 | 4.000 |
Why?
|
| Methadone | 16 | 2025 | 187 | 2.960 |
Why?
|
| Narcotic Antagonists | 11 | 2025 | 150 | 2.810 |
Why?
|
| Buprenorphine | 12 | 2025 | 162 | 2.640 |
Why?
|
| Opiate Substitution Treatment | 7 | 2025 | 114 | 2.050 |
Why?
|
| Naltrexone | 3 | 2025 | 70 | 1.980 |
Why?
|
| Substance Withdrawal Syndrome | 7 | 2025 | 168 | 1.890 |
Why?
|
| Disulfiram | 3 | 2025 | 13 | 1.630 |
Why?
|
| Double-Blind Method | 23 | 2025 | 729 | 1.400 |
Why?
|
| Alcohol Deterrents | 2 | 2025 | 10 | 1.300 |
Why?
|
| Sertraline | 3 | 2017 | 48 | 1.290 |
Why?
|
| Naloxone | 5 | 2013 | 85 | 1.200 |
Why?
|
| Narcotics | 11 | 2025 | 108 | 1.010 |
Why?
|
| Heart Rate | 3 | 2025 | 314 | 0.940 |
Why?
|
| Analgesics, Opioid | 7 | 2023 | 622 | 0.910 |
Why?
|
| Adult | 39 | 2026 | 14534 | 0.900 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2014 | 18 | 0.880 |
Why?
|
| Amines | 3 | 2014 | 38 | 0.880 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2014 | 61 | 0.860 |
Why?
|
| Methadyl Acetate | 3 | 2010 | 11 | 0.840 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2021 | 93 | 0.760 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2025 | 1367 | 0.740 |
Why?
|
| Video Games | 1 | 2022 | 14 | 0.730 |
Why?
|
| Middle Aged | 25 | 2026 | 13419 | 0.720 |
Why?
|
| Methamphetamine | 3 | 2021 | 190 | 0.720 |
Why?
|
| Cocaine | 7 | 2025 | 168 | 0.680 |
Why?
|
| Male | 37 | 2026 | 27435 | 0.660 |
Why?
|
| Female | 36 | 2026 | 28782 | 0.630 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 37 | 0.590 |
Why?
|
| Drug Monitoring | 1 | 2019 | 81 | 0.580 |
Why?
|
| Humans | 49 | 2026 | 53230 | 0.550 |
Why?
|
| Depression | 2 | 2014 | 621 | 0.530 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2007 | 54 | 0.530 |
Why?
|
| Outpatients | 3 | 2025 | 131 | 0.480 |
Why?
|
| Databases, Factual | 1 | 2019 | 742 | 0.470 |
Why?
|
| Remote Consultation | 1 | 2015 | 30 | 0.470 |
Why?
|
| Neurology | 1 | 2015 | 33 | 0.460 |
Why?
|
| Desipramine | 6 | 2005 | 26 | 0.440 |
Why?
|
| Isradipine | 2 | 2004 | 4 | 0.420 |
Why?
|
| Rural Health Services | 1 | 2015 | 179 | 0.400 |
Why?
|
| Diltiazem | 1 | 2013 | 10 | 0.400 |
Why?
|
| Verapamil | 1 | 2013 | 19 | 0.390 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 46 | 0.390 |
Why?
|
| Treatment Outcome | 11 | 2025 | 5595 | 0.390 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 530 | 0.390 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 57 | 0.380 |
Why?
|
| Electrocardiography | 1 | 2013 | 273 | 0.350 |
Why?
|
| Behavior Therapy | 2 | 2010 | 185 | 0.330 |
Why?
|
| Sodium Oxybate | 1 | 2010 | 11 | 0.330 |
Why?
|
| Pilot Projects | 8 | 2021 | 726 | 0.320 |
Why?
|
| Behavior | 1 | 2010 | 46 | 0.320 |
Why?
|
| Bupropion | 2 | 2007 | 34 | 0.320 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 74 | 0.310 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 640 | 0.300 |
Why?
|
| Benzhydryl Compounds | 1 | 2009 | 70 | 0.290 |
Why?
|
| Citalopram | 1 | 2007 | 17 | 0.260 |
Why?
|
| Drug Therapy, Combination | 5 | 2014 | 405 | 0.260 |
Why?
|
| Feedback | 2 | 2023 | 53 | 0.230 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2005 | 14 | 0.220 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 411 | 0.220 |
Why?
|
| Dextromethorphan | 1 | 2004 | 16 | 0.210 |
Why?
|
| Antidepressive Agents, Tricyclic | 5 | 2004 | 28 | 0.210 |
Why?
|
| Young Adult | 6 | 2026 | 4511 | 0.210 |
Why?
|
| Discrimination Learning | 1 | 2004 | 58 | 0.210 |
Why?
|
| Cycloserine | 1 | 2003 | 3 | 0.200 |
Why?
|
| Stress, Psychological | 1 | 2026 | 282 | 0.200 |
Why?
|
| Antimetabolites | 1 | 2003 | 12 | 0.200 |
Why?
|
| Behavior Control | 1 | 2003 | 3 | 0.200 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2014 | 42 | 0.200 |
Why?
|
| Tai Ji | 1 | 2023 | 22 | 0.200 |
Why?
|
| Behavior, Addictive | 1 | 2003 | 62 | 0.190 |
Why?
|
| Smoking Cessation | 1 | 2026 | 325 | 0.190 |
Why?
|
| Smoking | 1 | 2026 | 526 | 0.180 |
Why?
|
| Secondary Prevention | 2 | 2013 | 85 | 0.180 |
Why?
|
| Nalbuphine | 1 | 2002 | 2 | 0.180 |
Why?
|
| Butorphanol | 1 | 2002 | 6 | 0.180 |
Why?
|
| Dextroamphetamine | 1 | 2021 | 36 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2019 | 2411 | 0.180 |
Why?
|
| Emotions | 1 | 2023 | 177 | 0.180 |
Why?
|
| Placebos | 4 | 2011 | 80 | 0.170 |
Why?
|
| Heroin Dependence | 4 | 2006 | 46 | 0.170 |
Why?
|
| GABA Agonists | 2 | 2014 | 13 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 934 | 0.170 |
Why?
|
| Patient Compliance | 2 | 2014 | 232 | 0.170 |
Why?
|
| Self Report | 2 | 2013 | 225 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 333 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2021 | 143 | 0.160 |
Why?
|
| Psychomotor Agitation | 1 | 2020 | 51 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 254 | 0.160 |
Why?
|
| Blood Pressure | 3 | 2011 | 518 | 0.160 |
Why?
|
| Adolescent | 3 | 2022 | 6907 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 1 | 2021 | 201 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1049 | 0.150 |
Why?
|
| Antipsychotic Agents | 1 | 2020 | 233 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2022 | 6819 | 0.140 |
Why?
|
| Ambulatory Care | 3 | 2011 | 239 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2020 | 1368 | 0.140 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 7 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 185 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2010 | 185 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2019 | 183 | 0.120 |
Why?
|
| Analysis of Variance | 5 | 2004 | 547 | 0.120 |
Why?
|
| Mass Screening | 1 | 2019 | 362 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2011 | 325 | 0.120 |
Why?
|
| Transportation | 1 | 2015 | 30 | 0.120 |
Why?
|
| Time Factors | 3 | 2011 | 2991 | 0.120 |
Why?
|
| Travel | 1 | 2015 | 37 | 0.120 |
Why?
|
| Nipecotic Acids | 2 | 2006 | 2 | 0.110 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 77 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2015 | 108 | 0.110 |
Why?
|
| Cognition | 2 | 2023 | 346 | 0.110 |
Why?
|
| Anxiety | 2 | 2022 | 321 | 0.110 |
Why?
|
| Recurrence | 2 | 2014 | 694 | 0.100 |
Why?
|
| Directly Observed Therapy | 1 | 2013 | 5 | 0.100 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 52 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 623 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2013 | 52 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 65 | 0.100 |
Why?
|
| Calcium Channels, L-Type | 1 | 2013 | 68 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 136 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2013 | 196 | 0.090 |
Why?
|
| Depressive Disorder, Major | 2 | 2004 | 149 | 0.090 |
Why?
|
| Injections, Intramuscular | 2 | 2020 | 55 | 0.090 |
Why?
|
| Confusion | 1 | 2010 | 19 | 0.080 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2011 | 83 | 0.080 |
Why?
|
| Affect | 1 | 2011 | 107 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 487 | 0.080 |
Why?
|
| Respiration | 1 | 2010 | 94 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2010 | 126 | 0.080 |
Why?
|
| Arkansas | 1 | 2015 | 2068 | 0.080 |
Why?
|
| Sleep | 1 | 2011 | 195 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2026 | 1583 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2010 | 236 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 241 | 0.070 |
Why?
|
| Connecticut | 2 | 2005 | 17 | 0.070 |
Why?
|
| Progestins | 1 | 2007 | 10 | 0.070 |
Why?
|
| Progesterone | 1 | 2007 | 57 | 0.070 |
Why?
|
| Substance Abuse Detection | 2 | 2006 | 93 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2008 | 204 | 0.060 |
Why?
|
| Anti-Anxiety Agents | 1 | 2006 | 34 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2007 | 133 | 0.060 |
Why?
|
| Cues | 1 | 2006 | 56 | 0.060 |
Why?
|
| Urinalysis | 1 | 2005 | 33 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2007 | 336 | 0.050 |
Why?
|
| Linear Models | 2 | 2021 | 287 | 0.050 |
Why?
|
| GABA Agents | 1 | 2003 | 3 | 0.050 |
Why?
|
| Token Economy | 1 | 2003 | 33 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2023 | 85 | 0.050 |
Why?
|
| Tobacco Use Disorder | 1 | 2004 | 174 | 0.050 |
Why?
|
| Prognosis | 2 | 2005 | 2118 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2003 | 259 | 0.050 |
Why?
|
| Ketoconazole | 1 | 2002 | 10 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 1219 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2021 | 21 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 351 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 21 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 466 | 0.040 |
Why?
|
| California | 1 | 2019 | 93 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 121 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 502 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 1350 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 630 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 370 | 0.030 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2004 | 9 | 0.020 |
Why?
|
| Comorbidity | 2 | 2006 | 638 | 0.020 |
Why?
|
| Aged | 3 | 2019 | 10429 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 2006 | 11 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2006 | 56 | 0.010 |
Why?
|
| Reward | 1 | 2006 | 119 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 2004 | 24 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 194 | 0.010 |
Why?
|
| Receptors, Opioid, mu | 1 | 2004 | 53 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 338 | 0.010 |
Why?
|
| Psychometrics | 1 | 2004 | 244 | 0.010 |
Why?
|
| Receptors, Opioid | 1 | 2002 | 16 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 291 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 241 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2002 | 445 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2002 | 350 | 0.010 |
Why?
|